TargetBeta
ERBB3
erb-b2 receptor tyrosine kinase 3 · also HER3, LCCS2 · Erb-b2 receptor tyrosine kinases
12 programs in company-led studies act on ERBB3, from 11 companies: 5 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (9 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 5555 running | EGFR | a judged reading |
| patritumab deruxtecan | Merck | phase 3 | 1715 running | – | a judged reading |
| beruzatatug pelitecanrule | MediLink Therapeutics (Suzhou) | phase 3 | 99 running | – | NCIt |
| ruzaltatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 87 running | – | the company's pipeline |
| JSKN016rule | Alphamab Oncology | phase 3 | 55 running | TACSTD2 | the studies' text |
| SYS6023rule | CSPC Pharmaceutical Group | phase 2 | 22 running | – | the studies' text |
| Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418rule | Avenzo Therapeutics | phase 2 | 11 running | EGFR | NCIt |
| Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002rule | Xadcera Biopharmaceutical (Suzhou) | phase 2 | 11 running | MUC1 | NCIt |
| Anti-HER3/Exatecan Antibody-drug Conjugate ENV-501rule | Hummingbird Bioscience | phase 2 | 11 running | – | NCIt |
| KHN922rule | Chengdu Kanghong Pharmaceutical Group | phase 2 | 11 running | – | the studies' text |
| CS5007rule | CStone Pharmaceuticals | phase 1 | 11 running | EGFR | the studies' text |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 11 running | TACSTD2 | the studies' text |
Conditions their studies are in
- Breast Neoplasms, 6 programs
- Carcinoma, Non-Small-Cell Lung, 5 programs
- Melanoma, 3 programs
- Triple Negative Breast Neoplasms, 2 programs
- Carcinoma, Transitional Cell, 1 program
- Esophageal Neoplasms, 1 program
- Lung Neoplasms, 1 program
- Neoplasms, 1 program
- Ovarian Neoplasms, 1 program
- Small Cell Lung Carcinoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026izalontamab brengitecan · Sichuan Biokin Pharmaceutical · phase 3 · NCT06118333
- Nov 2026beruzatatug pelitecan · MediLink Therapeutics (Suzhou) · phase 3 · NCT06107686
- Dec 2026ruzaltatug rezetecan · Jiangsu HengRui Medicine · phase 3 · NCT06671379
- Jun 30, 2027JSKN016 · Alphamab Oncology · phase 3 · NCT06942234
- Jul 2027Anti-HER3/Exatecan Antibody-drug Conjugate ENV-501 · Hummingbird Bioscience · phase 2 · NCT06956690
- Sep 1, 2027patritumab deruxtecan · Merck · phase 3 · NCT06172478
- Oct 8, 2027Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002 · Xadcera Biopharmaceutical (Suzhou) · phase 2 · NCT06751329
- Nov 30, 2027SYS6023 · CSPC Pharmaceutical Group · phase 2 · NCT07597629
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.